Message #33 From:
Stock News Bot Date: March 26, 2007 06:30:00 AM
NPHC News Nutra Pharma Sponsors Educational Website about Tuberculosis (TB) in Conjunction with World TB Day
BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has announced that it has sponsored the website, stopTBnow.com, to educate the public about Tuberculosis (TB).
“Many people believe that Tuberculosis was a disease of the past,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “In fact, Tuberculosis, especially the drug-resistant XDR-TB strain, is a major concern for many developing countries that experience high rates of HIV infections,” he added.
The launch of stopTBnow.com coincides with World Tuberculosis Day, which was held on March 24, 2007. The website features information about Tuberculosis: its symptoms, diagnosis and treatments, as well as a list of organizations dedicated to eradicating the disease.
“New Tuberculosis (TB) infections are occurring at a rate of one per second and the disease accounts for over a million deaths each year,” explained Neil Roth, President of Designer Diagnostics. “We believe that one of the primary strategies for preventing the spread of the disease and saving patient lives is to educate the public about early detection and recognizing its symptoms,” he added.
In January, Designer Diagnostics announced the positive results of an in-vitro analysis of its Tuberculosis (TB) test kit. Normal culturing methods can take as long as 10 weeks to produce results, whereas Designer Diagnostics test kits showed similar results within 10 days.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC").The launch of StopTBnow.com should not be construed as an indication in any way whatsoever of the value of the Company or its common stock.The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
